{
  "source": "PA-Notification-Spevigo.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1446-2\nProgram Prior Authorization/Notification\nMedication *Spevigo® (spesolimab-sbzo) injection\n*This program applies to the subcutaneous formulations of Spevigo\nP&T Approval Date 5/2024, 5/2025\nEffective Date 7/1/2025\n1. Background:\nSpevigo is an interleukin-36 receptor antagonist indicated for the treatment of generalized\npustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing\nat least 40 kg.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Spevigo will be approved based upon both of the following criteria:\na. Diagnosis of generalized pustular psoriasis (GPP)\n-AND-\nb. Used for the treatment of GPP\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Spevigo will be approved based upon the following criterion:\na. Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Spevigo [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March\n2024.\nProgram Prior Authorization/Notification – Spevigo® (spesolimab-sbzo)\nChange Control\n5/2024 New program.\n5/2025 Annual review. Updated coverage criteria wording without change to\nclinical intent.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}